StockData
TELA Bio, Inc. logo

TELA Bio, Inc. (TELA) stock

TELANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$0.78+0.02 (+2.36%)

Close on Nov 18, 2026Market cap $35.02MP/E –Yield –

Earnings

TELA Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 23, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$19.00M
-8.2% on a year earlier
adjusted net loss per common share, Q3 FY2026
-$0.13
-$0.19 a year earlier
Latest guidance
Issued
Mar 24, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of TELA Bio's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Mar 23, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026after the close$19.00M-8.2%-$0.16-$0.13Release
Q2 FY2026ended Jun 30, 2026Aug 10, 2026after the close$19.30M-4.5%––Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026after the close––––Filing
Q4 FY2025ended Dec 31, 2025Mar 24, 2026after the close$20.90M+18.8%––Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025after the close$20.70M–-$0.19–Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025after the close$20.20M+25.5%––Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close$18.50M+11.4%––Release
Q4 FY2024ended Dec 31, 2024Mar 20, 2025after the close$17.60M+3.5%––Release
Q3 FY2024ended Sep 30, 2024Oct 22, 2024after the close––––Filing
Q2 FY2024ended Jun 30, 2024Aug 12, 2024after the close$16.10M+11.0%-$0.51–Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close$16.60M+39.5%-$0.23–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

TELA Bio's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenue growthFY2026+8%–NewMar 24, 2026

Guidance vs results

The last range TELA Bio gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q1 FY2025Revenue$17.00M – $18.00M$18.50MAbove range
Q1 FY2025Revenue growth+2% – +8%+11.45%Above range

Guidance history

Every forecast TELA Bio put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Mar 24, 2026revenue growthFY2026+8%New
Mar 24, 2026revenueQ1 FY2026$18.50MNew
Nov 13, 2025revenueFY2025+16%New
Aug 11, 2025revenueFY2025$85.00M – $88.00MReaffirmed
May 8, 2025revenue growthFY2025+23% – +27%Reaffirmed
May 8, 2025revenueFY2025$85.00M – $88.00MReaffirmed
Mar 20, 2025growthQ1 FY2025+2% – +8%New
Mar 20, 2025revenueQ1 FY2025$17.00M – $18.00MNew
Mar 20, 2025growthFY2025+23% – +27%New
Mar 20, 2025revenueFY2025$85.00M – $88.00MNew
Aug 12, 2024revenue guidanceFY2024$74.50M – $76.50MReaffirmed
May 9, 2024revenue guidanceFY2024$74.50M – $76.50MRaised
Mar 21, 2024revenueFY2024$74.00M – $76.00MNew
Nov 9, 2023revenueFY2023$57.00M – $60.00MLowered
Aug 9, 2023revenueFY2023$60.00M – $65.00MReaffirmed
May 11, 2023revenueFY2023$60.00M – $65.00MReaffirmed
Mar 21, 2023revenueFY2023$60.00M – $65.00MNew
Nov 9, 2022revenueFY2022$42.00M – $45.00MReaffirmed
Aug 10, 2022revenueFY2022$42.00M – $45.00MRaised
May 10, 2022revenueFY2022$40.00M – $45.00MReaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases TELA Bio filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. News
  3. Update
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Update
  14. Results
  15. Results

See a number that looks wrong?